The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
Open accessAbstract
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabelled peptide designed to target with high affinity and specificity receptors overexpressed on tumours. PRRNT employing the radiotagged somatostatin receptor agonists (90)Y-DOTATOC ([(90)Y-DOTA(0),Tyr(3)]-octreotide) or (177)Lu-DOTATATE ([(177)Lu-DOTA(0),Tyr(3),Thr(8)]-octreotide or [(177)Lu-DOTA(0),Tyr(3)]-octreotate) have been successfully used for the past 15 years to target metastatic or inoperable neuroendocrine tumours expressing the somatostatin receptor subtype 2. Accumulated evidence from clinical experience indicates that these tumours can be subjected to a high absorbed dose which leads to partial or complete objective responses in up to 30 % of treated patients. Survival analyses indicate that patients presenting with high tumour receptor expression at study entry and receiving (177)Lu-DOTATATE or (90)Y-DOTATOC treatment show significantly higher objective responses, leading to longer survival and improved quality of life. Side effects of PRRNT are typically seen in the kidneys and bone marrow. These, however, are usually mild provided adequate protective measures are undertaken. Despite the large body of evidence regarding efficacy and clinical safety, PRRNT is still considered an investigational treatment and its implementation must comply with national legislation, and ethical guidelines concerning human therapeutic investigations. This guidance was formulated based on recent literature and leading experts' opinions. It covers the rationale, indications and contraindications for PRRNT, assessment of treatment response and patient follow-up. This document is aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRRNT and to deliver the treatment in a safe and effective manner. This document is largely based on the book published through a joint international effort under the auspices of the Nuclear Medicine Section of the International Atomic Energy Agency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Self-citationRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Self-citationStabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,350
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840
Strosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L. (2011) · Cancer · doi:10.1002/cncr.25425 · Cited by 766
Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Siegel, J. A., Thomas, S. R., Stubbs, J. B., Mg, S., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., et al. (1999) · PubMed · Cited by 572
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513
Binderup, T., Knigge, U., Loft, A., Federspiel, B., & Kjaer, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1759 · Cited by 489
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100574 · Cited by 471
Self-citationSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466
Self-citationVirgolini, I., Ambrosini, V., Bomanji, J. B., Baum, R. P., Fanti, S., Gabriel, M., Papathanasiou, N. D., Pepe, G., Oyen, W., De Cristoforo, C., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1512-3 · Cited by 442
Self-citationValkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Self-citationKennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., et al. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815e4557 · Cited by 424
Yao, J. C., Phan, A., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S.-C. J., Hess, K., Ng, C., Abbruzzese, J. L., & Ajani, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6374 · Cited by 414
MODLIN, I. M., PAVEL, M., KIDD, M., & GUSTAFSSON, B. I. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 410
Self-citationPanel, N. I. O. H. S.-O.-T.-S. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg014 · Cited by 398
(2004) · Journal of the National Cancer Institute Monographs · doi:10.1093/jncimonographs/djg014 · Cited by 395
Kwekkeboom, D. J., Mueller‐Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S. A., Kvols, L. K., O’Dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., et al. (2005) · PubMed · Cited by 367
Self-citationMIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M., Green, A. J., Zanzonico, P. B., Frey, E. C., SNMMI MIRD Committee, Bolch, W. E., Brill, A. B., Dunphy, M., Fisher, D. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 336
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 332
Self-citationRolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0982-3 · Cited by 321
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Hicks, R. J., Van Cutsem, E., Baulieu, J.-L., Borson-Chazot, F., Anthony, L., Benson, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8585 · Cited by 306
Self-citationSteinmüller, T., Kianmanesh, R., Falconi, M., Scarpa, A., Taal, B., Kwekkeboom, D. J., Lopes, J. M., Perren, A., Nikou, G., Yao, J., et al. (2008) · Neuroendocrinology · doi:10.1159/000111037 · Cited by 296
Self-citationThe Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas
Moertel, C. G., Johnson, C. M., McKusick, M. A., Martin, J. K., Nagorney, D. M., Kvols, L. K., Rubin, J., & Kunselman, S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-4-199402150-00008 · Cited by 292
Sundin, A., Vullierme, M.-P., Kaltsas, G., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000184855 · Cited by 287
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases
King, J., Quinn, R., Glenn, D. M., Janssen, J., Tong, D., Liaw, W., & Morris, D. L. (2008) · Cancer · doi:10.1002/cncr.23685 · Cited by 284
Eriksson, B., Klöppel, G., Krenning, E., Ahlman, H., Plöckinger, U., Wiedenmann, B., Arnold, R., Auernhammer, C., Körner, M., Rindi, G., et al. (2008) · Neuroendocrinology · doi:10.1159/000111034 · Cited by 254
Jamar, F., Barone, R., Mathieu, I., Walrand, S., Labar, D., Carlier, P., Camps, J., Schran, H., Chen, T., Smith, M. C., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1117-1 · Cited by 240
Bajetta, E., Catena, L., Procopio, G., De Dosso, S., Bichisao, E., Ferrari, L., Martinetti, A., Platania, M., Verzoni, E., Formisano, B., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0306-6 · Cited by 240
Kunikowska, J., Królicki, L., Hubalewska-Dydejczyk, A., Mikołajczak, R., Sowa-Staszczak, A., & Pawlak, D. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1833-x · Cited by 238
A Systematic Review of the Comparative Safety of Colloids
Barron, M. E. (2004) · Archives of Surgery · doi:10.1001/archsurg.139.5.552 · Cited by 226
Bodei, L., Cremonesi, M., Grana, C., Rocca, P., Bartolomei, M., Chinol, M., & Paganelli, G. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1571-4 · Cited by 224
Self-citationBone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Forrer, F., Krenning, E. P., Kooij, P. P., Bernard, B. F., Konijnenberg, M., Bakker, W. H., Teunissen, J. J. M., de Jong, M., van Lom, K., de Herder, W. W., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1072-6 · Cited by 201
Self-citationDosimetry in Peptide radionuclide receptor therapy: a review.
Cremonesi, M., Ferrari, M. E., Bodei, L., Tosi, G., & Paganelli, G. (2006) · PubMed · Cited by 201
Self-citation111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
Bombardieri, E., Ambrosini, V., Aktolun, C., Baum, R. P., Bishof-Delaloye, A., Del Vecchio, S., Maffioli, L., Mortelmans, L., Oyen, W., Pepe, G., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1473-6 · Cited by 193
Self-citationRECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
van Persijn van Meerten, E. L., Gelderblom, H., & Bloem, J. L. (2010) · European Radiology · doi:10.1007/s00330-009-1685-y · Cited by 191
Givi, B., Pommier, S. J., Thompson, A. K., Diggs, B. S., & Pommier, R. F. (2006) · Surgery · doi:10.1016/j.surg.2006.07.033 · Cited by 189
Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2151 · Cited by 189
Interferon in the Management of Neuroendocrine GEP-Tumors
Öberg, K. (2000) · Digestion · doi:10.1159/000051862 · Cited by 187
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Sandström, M., Garske, U., Granberg, D., Sundin, A., & Lundqvist, H. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1216-8 · Cited by 182
Vogl, T. J., Naguib, N. N. N., Zangos, S., Eichler, K., Hedayati, A., & Nour-Eldin, N.-E. A. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.08.008 · Cited by 180
Wehrmann, C., Senftleben, S., Zachert, C., Müller, D., & Baum, R. P. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.325 · Cited by 177
Self-citation177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
Gains, J. E., Bomanji, J. B., Fersht, N. L., Sullivan, T., D'Souza, D., Sullivan, K. P., Aldridge, M., Waddington, W., & Gaze, M. N. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085100 · Cited by 170
Iten, F., Müller, B., Schindler, C., Rochlitz, C., Oertli, D., Mäcke, H. R., Müller-Brand, J., & Walter, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0935 · Cited by 170
Ruszniewski, P. B., Ish‐Shalom, S., Wymenga, M., O’Toole, D., Arnold, R., Tomassetti, P., Bax, N., Caplin, M. E., Eriksson, B. K., Gläser, B., et al. (2004) · Neuroendocrinology · doi:10.1159/000082875 · Cited by 154
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma
Bartolomei, M., Bodei, L., Cicco, C. D., Grana, C. M., Cremonesi, M., Botteri, E., Baio, S. M., Aricò, D., Sansovini, M., & Paganelli, G. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1115-z · Cited by 152
Self-citationFörster, G. J., Engelbach, M., Brockmann, J., Reber, H., Buchholz, H., Mäcke, H. R., Rösch, F., Herzog, H. R., & Bartenstein, P. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100628 · Cited by 149
Arnold, R., Chen, Y.-J., Costa, F. P., Falconi, M., Gross, D., Grossman, A. B., Hyrdel, R., Kos‐Kudła, B., Salazar, R., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225952 · Cited by 146
An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors
Eriksson, B. K., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083913 · Cited by 135
de Keizer, B., van Aken, M. O., Feelders, R. A., de Herder, W. W., Kam, B. L. R., van Essen, M., Krenning, E. P., & Kwekkeboom, D. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0691-z · Cited by 134
Self-citationvan Essen, M., Krenning, E. P., Bakker, W. H., de Herder, W. W., van Aken, M. O., & Kwekkeboom, D. J. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0355-4 · Cited by 133
Self-citationHelisch, A., F�rster, G., Reber, H., Buchholz, H., Arnold, R., G�ke, B., Weber, M. M., Wiedenmann, B., Pauwels, S. A., Haus, U., et al. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1561-6 · Cited by 133
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
Rolleman, E. J., Melis, M. L., Valkema, R., Boerman, O. C., Krenning, E. P., & de Jong, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1282-y · Cited by 131
Pavel, M. E., Baudin, É., Öberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx193 · Cited by 128
Self-citationDosimetry of internal emitters.
Sgouros, G. (2005) · PubMed · Cited by 127
Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
Maëcke, H. R., & Reubi, J. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.084236 · Cited by 125
Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine Tumors
Ruszniewski, P. B., & Malka, D. (2000) · Digestion · doi:10.1159/000051860 · Cited by 119
Peptide receptor therapies in neuroendocrine tumors
Bodei, L., Ferone, D., Grana, C. M., Cremonesi, M., Signore, A., Dierckx, R. A., & Paganelli, G. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345728 · Cited by 117
Self-citationWaser, B., Tamma, M., Cescato, R., Maëcke, H. R., & Reubi, J. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.061457 · Cited by 112
Ramage, J. K., Goretzki, P. E., Manfredi, R. M., et al. (2007) · Neuroendocrinology · doi:10.1159/000111036 · Cited by 108
Forrer, F., Uusij�rvi, H., Waldherr, C., Cremonesi, M., Bernhardt, P., Mueller‐Brand, J., & Maëcke, H. R. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1553-6 · Cited by 108
Self-citationKwekkeboom, D. J., Kooij, P. P. M., Bakker, W., Mäcke, H. R., & Krenning, E. P. (1999) · PubMed · Cited by 106
Self-citation(2010) · PubMed · Cited by 102
Eriksson, B. K., Annibale, B., Bajetta, E., Mitry, E., Pavel, M., Platania, M., Salazar, R., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225950 · Cited by 93
Self-citationNew advances in peptide receptor radionuclide therapy.
de Jong, M., & Krenning, E. P. (2002) · PubMed · Cited by 88
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
Walrand, S., Flux, G., Konijnenberg, M., Valkema, R., Krenning, E. P., Lhommel, R., Pauwels, S. A., & Jamar, F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1771-7 · Cited by 84
Menda, Y., O'Dorisio, M. S., Kao, S. C.-S., Khanna, G., Michael, S., Connolly, M., Babich, J. W., O’Dorisio, T. M., Bushnell, D. L., & Madsen, M. T. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075226 · Cited by 83
Self-citationFoster, D. M. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-1959-5_4 · Cited by 64
Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen, J. J. M., Kwekkeboom, D. J., Kooij, P. P. M., Bakker, W. H., & Krenning, E. P. (2005) · PubMed · Cited by 61
Self-citationKamat, P. P., Gupta, S. K., Ensor, J., Murthy, R., Ahrar, K., Madoff, D. C., Wallace, M. J., & Hicks, M. E. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-007-9186-3 · Cited by 57
Iten, F., Müller-Stich, B. P., Schindler, C., Rasch, H. F., Rochlitz, C. F., Oertli, D., Maëcke, H. R., Müller‐Brand, J., & Walter, M. A. (2009) · Cancer · doi:10.1002/cncr.24272 · Cited by 56
Rodrigues, M., Traub‐Weidinger, T., Li, S., Ibi, B., & Virgolini, I. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0020-3 · Cited by 49
Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function
Teunissen, J. J. M., Krenning, E. P., de Jong, F. H., de Rijke, Y. B., Feelders, R. A., van Aken, M. O., de Herder, W. W., & Kwekkeboom, D. J. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1151-8 · Cited by 49
Self-citationDosimetry For 90 Y-DOTATOC Therapies in Patients with Neuroendocrine Tumors
Hindorf, C., Chittenden, S. J., Causer, L., Lewington, V. J., Mäcke, H. R., & Flux, G. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.306 · Cited by 36
Giovacchini, G., Nicolas, G., Freidank, H., Mindt, T. L., & Forrer, F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1826-9 · Cited by 27
Radionuclide Peptide Cancer Therapy
(2013) · CRC Press eBooks · doi:10.3109/9781420016727 · Cited by 21
New advances in peptide receptor radionuclide therapy
Jong, M., & Krenning, E. (2002) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 7
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citationBaum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525
Self-citationEANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Kratochwil, C., Fendler, W. P., Eiber, M., Baum, R., Bozkurt, M. F., Czernin, J., Delgado Bolton, R. C., Ezziddin, S., Forrer, F., Hicks, R. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04485-3 · Cited by 387
Self-citationSadowski, S. M., Neychev, V., Millo, C., Shih, J., Nilubol, N., Herscovitch, P., Pacak, K., Marx, S. J., & Kebebew, E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0987 · Cited by 353
Hicks, R. J., Kwekkeboom, D. J., Krenning, E., Bodei, L., Grozinsky-Glasberg, S., Arnold, R., Borbath, I., Cwikla, J., Toumpanakis, C., Kaltsas, G., et al. (2017) · Neuroendocrinology · doi:10.1159/000475526 · Cited by 336
Self-citation
Metadata
- Authors
- Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., & Kwekkeboom, D. J.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2013-02-07
- Volume
- 40
- Issue
- 5
- Pages
- 800-816
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2090257199
- Cited by
- 818
- References
- 89
- FWCI
- 32.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.